Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 12
- Registration Number
- NCT04081753
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04079296
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Memorial Healthcare System-West, Pembroke Pines, Florida, United States
🇺🇸NYU Langone Health, New York, New York, United States
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- Conditions
- Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Solid TumorsNeuroblastoma
- Interventions
- Drug: Intrathecal Chemotherapy
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT04029688
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
🇺🇸Arnold Palmer Hosp-Children, Orlando, Florida, United States
A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT03987958
- Locations
- 🇮🇱
HaEmek Medical Center /ID# 213370, Afula, H_efa, Israel
🇮🇱Rambam Health Care Campus /ID# 213355, Haifa, H_efa, Israel
🇮🇱Bnai Zion Medical Center /ID# 213344, Haifa, H_efa, Israel
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03969420
- Locations
- 🇺🇸
Community Medical Providers, Clovis, California, United States
🇺🇸City of Hope National Medical Center, City of Hope Medical Center, Duarte, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)Cancer
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT03941964
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HOPE /ID# 211509, Tempe, Arizona, United States
🇺🇸Colorado Blood Cancer Institute /ID# 212800, Denver, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers /ID# 211508, Lone Tree, Colorado, United States
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- High-risk Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03940352
- Locations
- 🇺🇸
Duke University Medical Center ., Durham, North Carolina, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
- Conditions
- Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Nerviano Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT03922100
- Locations
- 🇫🇷
Centre Hospitalier du Mans, Le Mans, France
🇫🇷Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, France
🇫🇷CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque, Pessac, France
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT03915379
- Locations
- 🇪🇸
Hosp Clinic de Barcelona, Barcelona, Spain
🇪🇸Hosp Univ Vall D Hebron, Barcelona, Spain
🇪🇸Hosp Univ Fund Jimenez Diaz, Madrid, Spain
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT03896854
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China